Jane Street’s MiNK Therapeutics INKT Stock Holding History

Jane Street’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,839	Closed	-$19.7K	–	9616
2023 Q4	$19.7K	Buy	+1,839	New	+$19.2K	﹤0.01%	8911

Other funds holding INKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's INKT Position: Q1 2024 in Review

Jane Street sold out of MiNK Therapeutics (INKT) in Q1 2024, closing a stake of 1,839 shares — an estimated $19.7K sold.

Jane Street first reported a position in INKT in Q4 2023 and held it in 1 quarter. The position peaked at $19.7K in Q4 2023. 33 funds tracked by Wall St. Rank hold INKT as of Q1 2024.

Jane Street reported no remaining MiNK Therapeutics position as of Q1 2024 after selling out during the quarter.
Jane Street sold 1,839 MiNK Therapeutics shares in Q1 2024, an estimated $19.7K.
Jane Street first reported a position in MiNK Therapeutics in Q4 2023 and held it in 1 quarter.
Jane Street's MiNK Therapeutics position peaked at $19.7K in Q4 2023.
33 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2024.

Based on Jane Street's 13F filing for Q1 2024, filed 16 May 2024.